1 completed, 1 terminated. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow MEDI2070: new trials by email Literature Review of MEDI2070 trials Research Report on MEDI2070
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Efficacy and Safety of Brazikumab (MEDI2070) in Participants With Active, Moderate to Severe Crohn's Disease Brazikumab IV Infusion, Brazikumab SC Injection, Placebo - Crohn's Disease | Phase 2 | Terminated | AstraZeneca | 29 | 2016-01-05 | 2021-05-26 |
| Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease. MEDI2070, placebo - Crohn's Disease | Phase 2 | Completed | AstraZeneca | 121 | 2013-02-01 | 2021-05-26 |
Crohn Disease (2) · Inflammatory Bowel Diseases (2)
AstraZeneca (2)
Canada (2) · France (2) · Germany (2) · Hungary (2) · Italy (2) · Spain (2) · United States (2) · Australia (1) · Belgium (1) · Czechia (1) · Israel (1) · Netherlands (1) · Poland (1) · Russia (1)
2015 (1)